<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01773200</url>
  </required_header>
  <id_info>
    <org_study_id>P/2012/153</org_study_id>
    <nct_id>NCT01773200</nct_id>
  </id_info>
  <brief_title>Prognostic Value of Circulating Endothelial Progenitor Cells in Aneurysmal Subarachnoid Hemorrhage</brief_title>
  <acronym>EVAPROPEC</acronym>
  <official_title>Prognostic Value of Circulating Endothelial Progenitor Cells in Aneurysmal Subarachnoid Hemorrhage (Evaluation de l'intérêt Pronostic Des progéniteurs endothéliaux Circulants Dans l'hémorragie Sous-arachnoïdienne Par Rupture d'anévrysme cérébral)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aneurysmal subarachnoid hemorrhage is a common and serious disease associated to a high rate
      of mortality and morbidity. Severe definitive neurological impairment can concern up to 30%
      of patients in relation with elevated intracranial pressure, hemorrhage recurrence and
      symptomatic cerebral arterial vasospasm. This latter complication is defined as a reversible
      reduction of cerebral artery's diameter occurring between the 4th and the 14th day after
      bleeding. Physiopathology is not well understood, but could involve endothelium, trough
      endothelial progenitor cells (EPC). Circulating EPC are bone marrow-derived cells with
      capacity of vasculogenesis and angiogenesis. EPC have been recognized playing a beneficial
      role in cardiovascular disease and ischemic stroke. EPC have never been studied in aneurysmal
      subarachnoid hemorrhage.

      The primary objective of this study is to compare the number of circulating endothelial
      progenitor cells between patients with a good neurological outcome (defined as a glasgow
      outcome scale = 1 or 2) and patients with a poor neurological outcome (glasgow outcome scale
      = 3, 4 or 5).

      Briefly, the number of circulating EPC will be measured at admission, and at day 3, 6, 10,
      14, 21 in each consecutive patient suffering aneurysmal subarachnoid hemorrhage and
      hospitalized in Teaching Hospital of Besançon (France). The neurological outcome will be
      measured one year after subarachnoid hemorrhage.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>endothelial progenitor cells count</measure>
    <time_frame>day 3 after bleeding</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endothelial progenitor cells count</measure>
    <time_frame>day 0, 6, 10, 14, 21 after bleeding</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal amplitude of variation of EPC count</measure>
    <time_frame>3 weeks after bleeding</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasmatic brain natriuretic peptide</measure>
    <time_frame>day 0, 3, 6, 10, 14, 21 after bleeding</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Glasgow Outcome Scale</measure>
    <time_frame>One year after bleeding</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Vasospasm occurence</measure>
    <time_frame>during the 3 weeks after bleeding</time_frame>
    <description>Vasospasm will be defined as at less one segmental narrowing of a cerebral artery diagnosed on cerebral angiography (angio scanner, angio-MRI or 4 axes cerebral arteriography). Cerebral angiography will be done as necessary according to the occurence of the following situations
a clinical neurological deterioration unexplained by another cause
a mean arterial blood flow speed higher than 2 m/s assessed in cerebral arteries by transcranial doppler or a significant elevation of the mean arterial blood flow speed on two consecutive evaluations</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">92</enrollment>
  <condition>Aneurysmal Subarachnoid Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Aneurysmal Subarachnoid Hemorrhage</arm_group_label>
    <description>Each consecutive patient suffering from aneurysmal subarachnoid hemorrhage</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive patients suffering from acute aneurysmal subarachnoid haemorrhage. .
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  recent(&lt; 24 h) aneurysmal subarachnoid hemorrhage

          -  written informed consent obtained from the patient or from close relatives

        Exclusion Criteria:

          -  refusal to participate

          -  Non-aneurysmal subarachnoid hemorrhage

          -  aneurysmal subarachnoid hemorrhage with estimated date of bleeding &gt; 24 h

          -  Chronic heart failure

          -  Chronic medication able to modify the plasmatic level of BNP

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sébastien Pili-Floury, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU de Besançon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sébastien Pili-Floury, MD, PhD</last_name>
    <phone>+33 3 81 66 85 79</phone>
    <email>spilifloury@orange.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHRU de Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2013</study_first_submitted>
  <study_first_submitted_qc>January 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2013</study_first_posted>
  <last_update_submitted>March 29, 2016</last_update_submitted>
  <last_update_submitted_qc>March 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>endothelial progenitor cells</keyword>
  <keyword>aneurysmal subarachnoid hemorrhage</keyword>
  <keyword>vasospasm</keyword>
  <keyword>BNP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

